Skip to main content

B-cell precursor acute lymphoblastic leukemia (B-ALL) is a sort of cancer that is known to affect White Blood Cells (WBCs). It is characterized by the rapid and uncontrolled progression of immature B cells in the bone marrow as well as blood.

Blincyto (blinatumomab injection) is a medication that is used for treating B-ALL. It acts by targeting and binding to specific proteins on the surface of unhealthy B cells, which triggers an immune response that helps the body to find and kill these abnormal cells.

The medicine Blincyto is a type of immunotherapy named a bispecific T cell engager (BiTE). It works by bringing together T cells (a type of WBC that plays a vital role in the immune system) and unhealthy cells, allowing the T cells to find and attack the unhealthy cells.

Dosage of blincyto 38.5 mcg/35 mcg is typically given through a continuous infusion, which means it is delivered over a time span of several weeks. This treatment may be responsible for causing side effects, including chills, fever, and nausea, but these are generally manageable.

Overall, this pharmaceutical medicine has been shown to be promising in treating B-ALL, particularly in those who have not responded to other existing therapies. It is crucial to note, however, that not all patients with B-cell precursor acute lymphoblastic leukemia will be eligible for treatment with Blincyto, and treatment decisions need to be made in consultation with a health specialist.

How To Access/Source Blincyto:

Blincyto is a relatively new and life-saving drug and may not widely exist in India. Indian Pharma Network (IPN) has a global presence and can help provide information on the availability and sourcing of Blincyto. We facilitate patients connecting with reliable pharmaceutical wholesalers, dealers, and blincyto supplier in India and other places across the world. One can contact us directly either via our TOLL-FREE Number: 1800-889-1064 or Call/WhatsApp: +91 9310090915 to obtain information on sourcing Blincyto.

Nitin Goswami

Nitin Goswami joined us as an Editor in 2020. He covers all the updates in the field of Pharmaceutical, Business Healthcare, Health News, Medical News, and Pharma News.

Leave a Reply

Close Menu